Navigation Links
Perrigo Provides Update on Acquisition of Paddock Labs
Date:6/29/2011

ALLEGAN, Mich., June 29, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it continues to work to finalize  the regulatory approvals necessary to complete the acquisition of Paddock Laboratories, Inc. ("Paddock"), a privately-held, Minneapolis-based pharmaceutical manufacturer of generic Rx pharmaceuticals and OTC specialty products.

Perrigo Chairman and CEO Joseph C. Papa stated, "We are looking forward to concluding the transaction as soon as possible. As we previously stated, we expect the transaction to be $0.25 accretive to adjusted earnings per share in fiscal year 2012. We have recently received a few additional questions from the Federal Trade Commission Staff and the Parties are working collaboratively with the Staff to answer these questions so that the FTC may conclude its review.  Since the close will now happen in our fiscal year 2012, we expect to incur $0.20 of deal-related intangible amortization and $0.15 of other acquisition-related costs, making it approximately $0.10 dilutive to GAAP earnings per share. Perrigo's stated goal of Return on Invested Capital accretion is expected to be achieved in fiscal 2013. This acquisition is an important step forward in executing Perrigo's strategy to expand our specialty portfolio of generic Rx products. It adds incremental scale, as well as excellent development and manufacturing capabilities across a spectrum of niche dosage forms. It solidifies Perrigo's leading position in the extended topical space and strengthens our ability to offer new products into the market. Paddock has a proven record for quality manufacturing with great customer service."

As previously highlighted, Perrigo expects to receive a significant tax benefit generated from the acquisition of Paddock's assets. The net present value of the tax benefit is estimated to be $95 million. Inclusive of the tax benefit, the total consideration for the acquisition is approximately $445 million.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).  

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 26, 2010, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Announces Launch of the Generic Version of Nasacort® AQ
2. Perrigo Company to Present at the Goldman Sachs 32nd Annual Global Health Care Conference
3. Perrigos Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution
4. Perrigo Announces FDA Final Approval for Ranitidine 150 - Generic Equivalent to Zantac 150®
5. Perrigo Announces Settlement of Cutivate Lotion Litigation
6. Perrigo to Introduce New Dosing System and Labeling for Certain Pediatric Pain Relievers
7. Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance
8. Perrigo Announces FDA Final Approval for Minoxidil Foam - Generic Equivalent to Mens Rogaine® Foam
9. Perrigo Company Announces Quarterly Dividend
10. Perrigos PBM Infant Formula Unit Wins Appellate Judgment Versus Mead Johnson
11. Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , March 30, 2017 The topical ... $92.40 billion in 2016, growing at a CAGR of 6.4% ... is will be major end-user in market. While ... forecast period. ... Browse 87 tables and 41 figures, 10 Company profiles ...
(Date:3/30/2017)... -- Research and Markets has announced the addition ... Forecast, By Type (Hemodialysis, Peritoneal Dialysis), By Product (Device, Consumables, ... To 2025" report to their offering. ... The global hemodialysis ... billion by 2025. Home-based dialysis treatment ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... ... energy-based aesthetic devices market to grow at a CAGR of 8.12% ... Aesthetic Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... During the last week of March, Chad ... to eligible individuals in the local community. , Colon cancer is the second ... detect colon cancer while it is small, confined and easier to treat. If you ...
(Date:3/29/2017)... ... 29, 2017 , ... In the United States alone, up to 36% of ... types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors are ... more effective treatment options, the San Diego Gamma Knife Center offers a ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... Full Contact ... founder of Pet Protect Law that assists dog owners in creating legally-enforceable ... new owners in taking the natural next step to protect their new companion. Says ...
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS ... Medical Center will serve as the official title sponsor of the Baltimore Women’s Classic, ... 2017, thousands of women will walk or run the course around the Baltimore Inner ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sublime Naturals ... "Spice of Life" or "Wonder Spice", it has been used for thousands of years. ... the East," says Heshelow, author of " Turmeric: How to Use it For Your ...
Breaking Medicine News(10 mins):